JAK2 and neoplasm: For example, a study by Navarro et al. found that miR-135a can function as a tumor suppressor by targeting JAK2 to suppress STAT3 activation, and showed that the expression of cyclin D1 and Bcl-xL was reduced in classic Hodgkin’s lymphoma.